NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Cui XP, Ye JX, Lin H, Mu JS, Lin M. Efficacy, safety, and tolerability of Telcagepant in the treatment of acute migraine: a meta-analysis. Pain Practice 2013: epub. [PubMed: 24382126]
Abstract
Although triptans are widely used for treating acute migraine, they are contraindicated or not effective in a large proportion of patients. Hence, alternative treatments are needed. Calcitonin gene-related peptide receptor antagonists, such as telcagepant, have been under investigation as a treatment for acute migraine. A meta-analysis of the efficacy of telcagepant vs. placebo and triptans (zolmitriptan or rizatriptan) was performed. Randomized controlled trials were indentified from databases using the following search terms: migraine; calcitonin gene-related peptide; calcitonin gene-related peptide receptor antagonists; efficacy; safety, and telcagepant. The primary outcome measure was pain freedom 2 hours after first treatment. The secondary outcome measure was pain relief 2 hours after first treatment. Eight trials were included in the meta-analysis (telcagepant = 4011 participants). The difference in pain freedom at 2 hours significantly favored telcagepant over placebo (odds ratio = 2.70, 95% confidence interval = 2.27-3.21, P < 0.001) and triptans over telcagepant (odds ratio = 0.68, 95% confidence interval = 0.56-0.83, P < 0.001). The difference in pain relief at 2 hours significantly favored telcagepant over placebo (odds ratio = 2.48, 95% confidence interval = 2.18-2.81, P < 0.001). The difference in pain relief at 2 hours did not significantly favor telcagepant over triptans or vice versa (odds ratio = 0.76, 95% confidence interval = 0.57-1.01, P = 0.061). These findings indicate that telcagepant can be effective for treating acute migraine. Calcitonin gene-related peptide receptor antagonists represent a potentially important alternative means of treating acute migraine.
© 2013 World Institute of Pain.
- Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.[Lancet. 2008]Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, et al. Lancet. 2008 Dec 20; 372(9656):2115-23. Epub 2008 Nov 25.
- Review Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.[Headache. 2011]Review Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.Tfelt-Hansen P. Headache. 2011 Jan; 51(1):118-23. Epub 2010 Nov 10.
- Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.[Cephalalgia. 2011]Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.Dodick DW, Kost J, Assaid C, Lines C, Ho TW. Cephalalgia. 2011 Feb; 31(3):296-300. Epub 2010 Oct 11.
- Review Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment.[J Headache Pain. 2011]Review Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment.Tfelt-Hansen P. J Headache Pain. 2011 Jun; 12(3):275-80. Epub 2011 Feb 25.
- Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.[Headache. 2012]Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora SK, Brandes JL, Fei K, et al. Headache. 2012 Feb; 52(2):224-35. Epub 2012 Jan 6.
- Efficacy, safety, and tolerability of Telcagepant in the treatment of acute migr...Efficacy, safety, and tolerability of Telcagepant in the treatment of acute migraine: a meta-analysis - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...